{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:59:53Z","timestamp":1774522793190,"version":"3.50.1"},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with prostate cancer (PCa) have a lower docetaxel exposure for both intravenous (1.8\u2010fold) and oral administration (2.4\u2010fold) than patients with other solid cancers, which could influence efficacy and toxicity. An altered metabolism by cytochrome P450 3A (CYP3A) due to castration status might explain the observed difference in docetaxel pharmacokinetics. In this in vivo phenotyping, pharmacokinetic study, CYP3A activity defined by midazolam clearance (CL) was compared between patients with PCa and male patients with other solid tumors. All patients with solid tumors who did not use CYP3A\u2010modulating drugs were eligible for participation. Patients received 2 mg midazolam orally and 1 mg midazolam intravenously on 2 consecutive days. Plasma concentrations were measured with a validated liquid chromatography\u2013tandem mass spectrometry method. Genotyping was performed for CYP3A4 and CYP3A5. Nine patients were included in each group. Oral midazolam CL was 1.26\u2010fold higher in patients with PCa compared to patients with other solid tumors (geometric mean [coefficient of variation], 94.1 [33.5%] L\/h vs 74.4 [39.1%] L\/h, respectively; <jats:italic>P<\/jats:italic>\u00a0= .08). Intravenous midazolam CL did not significantly differ between the 2 groups (<jats:italic>P<\/jats:italic> = .93). Moreover, the metabolic ratio of midazolam to 1\u2032\u2010hydroxy midazolam did not differ between the 2 groups for both oral administration (<jats:italic>P<\/jats:italic> = .67) and intravenous administration (<jats:italic>P<\/jats:italic> = .26). CYP3A4 and CYP3A5 genotypes did not influence midazolam pharmacokinetics. The observed difference in docetaxel pharmacokinetics between both patient groups therefore appears to be explained neither by a difference in midazolam CL nor by a difference in metabolic conversion rate of midazolam.<\/jats:p>","DOI":"10.1002\/jcph.2362","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T09:15:56Z","timestamp":1696410956000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam"],"prefix":"10.1002","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-8101","authenticated-orcid":false,"given":"Lisa T.","family":"van der Heijden","sequence":"first","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Division of Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire A.","family":"Ribbers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Division of Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marit A.C.","family":"Vermunt","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Division of Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"Pluim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Division of Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Acda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Division of Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs","family":"Tibben","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Division of Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Division of Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joeri A.J.","family":"Douma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Division of Medical Oncology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  The Netherlands"},{"name":"Department of Internal Medicine Medisch Centrum Leeuwarden  Leeuwarden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kishan","family":"Naipal","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Division of Medical Oncology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre M.","family":"Bergman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Division of Medical Oncology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  The Netherlands"},{"name":"Department of Oncogenomics The Netherlands Cancer Institute  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Division of Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Division of Pharmaco\u2010epidemiology and Clinical Pharmacology Faculty of Science Department of Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Division of Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam The Netherlands"},{"name":"Department of Clinical Pharmacy University Medical Center Utrecht Utrecht University  Utrecht The Netherlands"},{"name":"Department of Pharmacology Princess Maxima Center  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans L.","family":"Opdam","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Division of Medical Oncology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"e_1_2_10_2_1","article-title":"Taxotere, INN\u2010docetaxel \u2013 European Medicines Agency","author":"Sanofi\u2010Aventis","year":"2005","journal-title":"Summary of product characteristics"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.8251"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj115"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.09.010"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2299"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2011.08.041"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1367"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04259-5"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2003"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04433-3"},{"issue":"1","key":"e_1_2_10_12_1","first-page":"58","article-title":"Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs","volume":"56","author":"Royer I","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000093"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.7025"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0613-6"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.94"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100148"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.06.002"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.068601"},{"issue":"1","key":"e_1_2_10_20_1","first-page":"549","article-title":"Use of midazolam as a human cytochrome P450 3A probe: I. In vitro\u2010in vivo correlations in liver transplant patients","volume":"271","author":"Thummel KE","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"e_1_2_10_21_1","first-page":"557","article-title":"Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter\u2010 and intraindividual hepatic CYP3A variability after liver transplantation","volume":"271","author":"Thummel KE","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2016.1163337"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2743"},{"key":"e_1_2_10_24_1","unstructured":"Agency EEM.Guideline on Bioanalytical Method Validation.Committee for Medicinal Products for Human Use and European Medicines Agency. Accessed May 8 2022."},{"key":"e_1_2_10_25_1","unstructured":"Administration FFaD.Bioanalytical Method Validation.Silver Springs Maryland:US Food and Drug Administration. Accessed May 9 2022."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.02.005"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12611"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.021816"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0767-7"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2323-2"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.13.133"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.230"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.46"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32834300cc"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.080895"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1210\/me.2010-0367"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00011-13"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02774-2"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2341"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01737-1"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03905-3"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.081935"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00944"},{"key":"e_1_2_10_45_1","unstructured":"European Medicines Agency.Guideline on the investigation of drug interactions.European Medicines Agency (EMA). Accessed February 27 2023."},{"key":"e_1_2_10_46_1","unstructured":"Guidance for industry drug interaction studies \u2013 study design data analysis implications for dosing and labeling recommendations.US Food and Drug Administration (FDA). Accessed February 27 2023."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T08:55:34Z","timestamp":1706518534000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1002\/jcph.2362"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2362","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"2023-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}